Genentech, Inc. is a renowned organization in the field of biomedicine, specializing in the development of innovative pharmaceutical products.

This article summarized the latest R&D progress of Pralsetinib, the Mechanism of Action for Pralsetinib, and the drug target R&D trends for Pralsetinib.

Zenas BioPharma disclosed today their signing of a licensing and partnership contract with Bristol Myers Squibb Company.

AHR agonists have shown effects in some representative models of autoimmune diseases (including systemic lupus erythematosus, Behcet's syndrome, multiple sclerosis, inflammatory bowel disease, etc.)

Genmab A/S and Seagen Inc.  revealed that its main objective of overall survival when TIVDAK®(tisotumab vedotin-tftv) was used in comparison to chemotherapy only.

Eisai, Inc. is a multinational company headquartered in Tokyo and founded in 1941 with overseas branches, subsidiaries and factories throughout Europe, America and Asia.

This article summarized the latest R&D progress of Pralatrexate, the Mechanism of Action for Pralatrexate, and the drug target R&D trends for Pralatrexate.

The multinational healthcare firm, Viatris Inc., has shared news of the tentative approval from FDA)for an abacavir 60 mg/dolutegravir 5 mg/lamivudine 30 mg oral suspension tablet New Drug Application .

The 5-HT1A receptor is one of the most widely distributed 5-HT receptors, present on the cell bodies and dendrites of 5-HT neurons, situated in the raphe nucleus and the terminal location of 5-HT release.

Swedish precision oncology firm, Beactica Therapeutics AB, has today unveiled BEA-17 as their chosen preclinical candidate within the LSD1 initiative

Daiichi Sankyo Co., Ltd. is a pharmaceutical organization based in Tokyo-to, Japan.

ACM Biolabs has revealed encouraging preliminary findings from a Phase I evaluation of ACM-001, their inaugural clinical-stage development initiative.